Skip to main content
Search
Site Search
Singapore | en
Choose Location
Americas
Asia Pacific
Europe
International
Middle East & Africa
Argentina |
Español
Brazil |
Português
Canada |
English
Canada |
Français
Andean & CAC |
Español
Colombia |
Español
Mexico |
Español
United States |
English
Australia |
English
Hong Kong S.A.R. |
繁體中文
India |
English
Indonesia |
English
Japan |
日本語
Korea |
한국어
Mainland China |
中文
Malaysia |
English
Philippines |
English
Singapore |
English
Taiwan |
繁體中文
Thailand |
ภาษาไทย
Austria |
Deutsch
Belgium |
Français
Belgium |
Nederlands
Bulgaria |
Български
Czech Republic |
Česky
Czech Republic |
English
Denmark |
Dansk
Estonia |
Eesti
Finland |
Suomalainen
France |
Français
Germany |
Deutsch
Greece |
Ελληνικά
Hungary |
Magyar
Ireland |
English
Italy |
Italiano
Latvia |
Latvian
Lithuania |
Lithuanian
Netherlands |
Nederlands
Norway |
Norsk
Poland |
Polski
Portugal |
Português
Romania |
Română
Russia |
Русский
Serbia |
Srpski
Slovakia |
Slovensky
Slovenia |
Slovenščina
Slovenia |
English
Spain |
Español
Sweden |
Svenska
Switzerland |
Deutsch
Switzerland |
Français
Türkiye |
Türkçe
Ukraine |
українська
United Kingdom |
English
Global |
English
Novartis Foundation |
English
Egypt |
English
Israel |
עברית
Saudi Arabia |
العربية
South Africa |
English
Singapore
Choose Location
asia-pacific
Americas
Asia Pacific
Europe
International
Middle East & Africa
Argentina |
Español
Australia |
English
Austria |
Deutsch
Belgium |
Français
Belgium |
Nederlands
Brazil |
Português
Bulgaria |
Български
Canada |
English
Canada |
Français
Andean & CAC |
Español
Colombia |
Español
Czech Republic |
Česky
Czech Republic |
English
Denmark |
Dansk
Egypt |
English
Estonia |
Eesti
Finland |
Suomalainen
France |
Français
Germany |
Deutsch
Greece |
Ελληνικά
Hong Kong S.A.R. |
繁體中文
Hungary |
Magyar
India |
English
Indonesia |
English
Ireland |
English
Israel |
עברית
Italy |
Italiano
Japan |
日本語
Korea |
한국어
Latvia |
Latvian
Lithuania |
Lithuanian
Mainland China |
中文
Malaysia |
English
Mexico |
Español
Netherlands |
Nederlands
Norway |
Norsk
Global |
English
Novartis Foundation |
English
Philippines |
English
Poland |
Polski
Portugal |
Português
Romania |
Română
Russia |
Русский
Saudi Arabia |
العربية
Serbia |
Srpski
Singapore |
English
Slovakia |
Slovensky
Slovenia |
Slovenščina
Slovenia |
English
South Africa |
English
Spain |
Español
Sweden |
Svenska
Switzerland |
Deutsch
Switzerland |
Français
Taiwan |
繁體中文
Thailand |
ภาษาไทย
Türkiye |
Türkçe
Ukraine |
українська
United Kingdom |
English
United States |
English
Menu
About
Novartis in Singapore
Strategy
Diversity and Inclusion
People and Culture
Products
Contact
About
Patients and Caregivers
Novartis Commitment to Patients and Caregivers
Diseases
Education and Awareness
Patient resources
Adverse Event Reporting
Patients and Caregivers
Healthcare Professionals
Healthcare professional country resource
Products
Adverse Event Reporting
Novartis Clinical Trials
Healthcare Professionals
ESG
Ethical Behavior
Code of Ethics
SpeakUp
Ethics, Risk and Compliance
Access
Environmental Sustainability
Global Health
News
News Archive
Stories
Contacts
News
Careers
Career Search
Meet the teams
Early Talent
How We Work
Diversity and Inclusion
Awards and Recognition
Careers
Coronavirus
Coronavirus
Home
Home
About
Product Listing in Singapore
Global Product Portfolio
Showing 83 results
All Products
Active Ingredients
Disease Area
Division
A-Z
Omalizumab
XOLAIR
(Omalizumab)
Pharma
More Information
Package Insert
(PDF 1.46 MB)
Onasemnogene abeparvovec
ZOLGENSMA®
(Onasemnogene abeparvovec)
Pharma
More Information
Package Insert
(PDF 658.74 KB)
Ceritinib
ZYKADIA
(Ceritinib)
Oncology
More Information
Package Insert
(PDF 1.31 MB)
Pagination
‹
Previous page
1
…
3
4
5
6
7
8
9
›
Next page